The Role of Luspatercept as First-Line Treatment in Lower-Risk MDS

EP: 1.Overview of Low-Risk MDS: Clinical Hallmarks and Current Treatments

EP: 2.Incorporating Prognostic Scoring Systems in Treatment Decisions for Lower-Risk MDS

Now Viewing

EP: 3.The Role of Luspatercept as First-Line Treatment in Lower-Risk MDS

EP: 4.Impact of Improved Hemoglobin Levels on Patient Well-being and Quality of Life

EP: 5.Approaches to Initiating and Adjusting Luspatercept Dosing

EP: 6.Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)

EP: 7.Advancing the Treatment Landscape for Lower-Risk MDS: Unmet Needs and Future Directions

EP: 8.Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating Agents

Video content above is prompted by the following question(s):

Luspatercept has been available to treat anemia in LR MDS after failing an ESA since 2020. Later in 2023, it was approved as first-line treatment for anemia in LR MDS for patients who may require transfusions.

Please discuss the role of luspatercept in the 1L treatment of lower-risk MDS patients, particularly those RS+/RS-; serum EPO ≤200 mU/L

• What are your thoughts on the efficacy and potential benefits of luspatercept in this patient population?

• Please discuss the how mutational burden impacts response and duration of response in the COMMANDS trial.